118 related articles for article (PubMed ID: 15997656)
1. [The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation].
Mikamo H; Totsuka K
Jpn J Antibiot; 2005 Apr; 58(2):159-67. PubMed ID: 15997656
[TBL] [Abstract][Full Text] [Related]
2. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
4. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Kuti JL; Florea NR; Nightingale CH; Nicolau DP
Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
[TBL] [Abstract][Full Text] [Related]
7. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
8. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
Ohata Y; Tomita Y; Nakayama M; Kozuki T; Sunakawa K; Tanigawara Y
Drug Metab Pharmacokinet; 2011; 26(5):523-31. PubMed ID: 21747200
[TBL] [Abstract][Full Text] [Related]
9. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Kuti JL; Nicolau DP
Chemotherapy; 2005 Jul; 51(4):211-6. PubMed ID: 15985760
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
12. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Santos Filho L; Eagye KJ; Kuti JL; Nicolau DP
Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
[TBL] [Abstract][Full Text] [Related]
13. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
[TBL] [Abstract][Full Text] [Related]
14. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
15. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
Kiffer CR; Mendes C; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
19. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.
Kuti JL; Maglio D; Nightingale CH; Nicolau DP
Am J Health Syst Pharm; 2003 Mar; 60(6):565-8. PubMed ID: 12659058
[TBL] [Abstract][Full Text] [Related]
20. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
